131 related articles for article (PubMed ID: 25512369)
1. Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
Baker JE; Su J; Koprowski S; Dhanasekaran A; Aufderheide TP; Gross GJ
J Pharmacol Exp Ther; 2015 Mar; 352(3):429-37. PubMed ID: 25512369
[TBL] [Abstract][Full Text] [Related]
2. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
[TBL] [Abstract][Full Text] [Related]
3. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Matsuki E; Miyakawa Y; Yamane A; Okamoto S
Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
6. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
Xie CY; Xu YP; Zhao HB; Lou LG
Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
8. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
[TBL] [Abstract][Full Text] [Related]
9. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
Zuo S; Sun L; Wang Y; Chen B; Wang J; Ge X; Lu Y; Yang N; Shen P
Cell Death Dis; 2021 Feb; 12(2):208. PubMed ID: 33627636
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
12. Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent.
Ko HT; Hsu LH; Yang SY; Chen YL
Med Mycol; 2020 Jun; 58(4):493-504. PubMed ID: 31297540
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells.
Guenther KL; Cheruku PS; Cash A; Smith RH; Alvarado LJ; Burkett S; Townsley DM; Winkler T; Larochelle A
Exp Hematol; 2019 May; 73():1-6.e6. PubMed ID: 30986494
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.
Alvarado LJ; Huntsman HD; Cheng H; Townsley DM; Winkler T; Feng X; Dunbar CE; Young NS; Larochelle A
Blood; 2019 May; 133(19):2043-2055. PubMed ID: 30803992
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
[TBL] [Abstract][Full Text] [Related]
17. MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491.
Levy G; Carillo S; Papoular B; Cassinat B; Zini JM; Leroy E; Varghese LN; Chachoua I; Defour JP; Smith SO; Constantinescu SN
Blood; 2020 Mar; 135(12):948-953. PubMed ID: 31978223
[TBL] [Abstract][Full Text] [Related]
18. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes.
Karliner JS; Honbo N; Summers K; Gray MO; Goetzl EJ
J Mol Cell Cardiol; 2001 Sep; 33(9):1713-7. PubMed ID: 11549349
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
Sugita M; Kalota A; Gewirtz AM; Carroll M
Leukemia; 2013 Apr; 27(5):1207-10. PubMed ID: 23183425
[No Abstract] [Full Text] [Related]
20. Hetrombopag, a Thrombopoietin Receptor Agonist, Protects Cardiomyocyte Survival from Oxidative Stress Damage as an Enhancer of Stem Cells.
Zhou N; Wang J; Li X; Zhao Y; Sun Y; Zou C
Cardiovasc Drugs Ther; 2016 Dec; 30(6):567-577. PubMed ID: 27838864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
